Clinical experience with superior vena caval Greenfield filters.

E Ascher, A Hingorani, F Mazzariol, T Jacob, W Yorkovich, P Gade
{"title":"Clinical experience with superior vena caval Greenfield filters.","authors":"E Ascher,&nbsp;A Hingorani,&nbsp;F Mazzariol,&nbsp;T Jacob,&nbsp;W Yorkovich,&nbsp;P Gade","doi":"10.1583/1074-6218(1999)006<0365:CEWSVC>2.0.CO;2","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the results of superior vena caval (SVC) Greenfield filters in patients at risk for pulmonary embolism (PE) secondary to upper extremity deep venous thrombosis (UEDVT).</p><p><strong>Methods: </strong>Over a 46-month period, 26 patients (10 men, mean age 67 years, range 25 to 89) with UEDVT in whom anticoagulation was contraindicated (n = 22) or ineffective in preventing recurrent PE or extension of the thrombus (n = 4) were treated with placement of SVC Greenfield filters.</p><p><strong>Results: </strong>One SVC filter was misplaced into the innominate vein but left in place; this vein remains patent after 2 months without evidence of filter migration. Follow-up ranged from 10 days to 46 months (mean 7.8 months). Fifteen (58%) patients died inhospital of causes unrelated to the SVC filter or recurrent thromboembolism (mean time to death 36 days). Of the 11 survivors, follow-up ranged from 1 to 38 months (mean 22). Sequential chest roentgenograms in 9 (82%) patients revealed no filter migration or displacement. No evidence of PE was found in any of the survivors over the course of follow-up.</p><p><strong>Conclusions: </strong>Insertion of SVC Greenfield filters is a safe and feasible therapy to prevent recurrent thromboembolism in patients with UEDVT who are refractory to or inappropriate for anticoagulation therapy.</p>","PeriodicalId":79443,"journal":{"name":"Journal of endovascular surgery : the official journal of the International Society for Endovascular Surgery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1999-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of endovascular surgery : the official journal of the International Society for Endovascular Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1583/1074-6218(1999)006<0365:CEWSVC>2.0.CO;2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 22

Abstract

Purpose: To evaluate the results of superior vena caval (SVC) Greenfield filters in patients at risk for pulmonary embolism (PE) secondary to upper extremity deep venous thrombosis (UEDVT).

Methods: Over a 46-month period, 26 patients (10 men, mean age 67 years, range 25 to 89) with UEDVT in whom anticoagulation was contraindicated (n = 22) or ineffective in preventing recurrent PE or extension of the thrombus (n = 4) were treated with placement of SVC Greenfield filters.

Results: One SVC filter was misplaced into the innominate vein but left in place; this vein remains patent after 2 months without evidence of filter migration. Follow-up ranged from 10 days to 46 months (mean 7.8 months). Fifteen (58%) patients died inhospital of causes unrelated to the SVC filter or recurrent thromboembolism (mean time to death 36 days). Of the 11 survivors, follow-up ranged from 1 to 38 months (mean 22). Sequential chest roentgenograms in 9 (82%) patients revealed no filter migration or displacement. No evidence of PE was found in any of the survivors over the course of follow-up.

Conclusions: Insertion of SVC Greenfield filters is a safe and feasible therapy to prevent recurrent thromboembolism in patients with UEDVT who are refractory to or inappropriate for anticoagulation therapy.

上腔静脉格林菲尔德过滤器的临床应用体会。
目的:评价上腔静脉(SVC) Greenfield过滤器在上肢深静脉血栓(UEDVT)继发肺栓塞(PE)风险患者中的效果。方法:在46个月的时间里,26例UEDVT患者(10名男性,平均年龄67岁,范围25至89岁),抗凝治疗禁忌(n = 22)或对预防PE复发或血栓扩展无效(n = 4),放置SVC Greenfield过滤器进行治疗。结果:1个SVC滤光片错位进入无名静脉,但仍留在原位;2个月后静脉通畅,无滤过物迁移。随访10天至46个月(平均7.8个月)。15例(58%)患者死于与SVC滤过器无关的原因或复发性血栓栓塞(平均死亡时间36天)。在11名幸存者中,随访时间为1至38个月(平均22个月)。9例(82%)患者的序贯胸片显示没有滤过膜迁移或移位。在随访过程中,没有发现任何幸存者有PE的证据。结论:对于抗凝治疗难治性或不适合抗凝治疗的UEDVT患者,植入SVC Greenfield滤过器是一种安全可行的预防血栓复发的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信